by Lou Basenese | Jul 25, 2019 | PRVB
If you’re prone to paranoia selling, print out this rundown on Provention Bio (PRVB) and slap it on the fridge next to the pictures of the grandkids to keep you from doing anything stupid in the next 21 days.
by Lou Basenese | Jun 13, 2019 | PRVB
Management at Provention Bio (PRVB) jumped the gun on the capital raise. But thankfully they ranked it to avoid unnecessary dilution. Here’s why DTR believes it was a bullish move…
by Lou Basenese | Jun 10, 2019 | PRVB
Management at Provention Bio (PRVB) jumped the gun on the capital raise after the positive readout for “At-Risk” patients for Type 1 Diabetes, but here’s why it will work out ok…
by Lou Basenese | Jun 9, 2019 | PRVB
New data on Teplizumab represents biggest breakthrough in the treatment of Type 1 Diabetes since the introduction of insulin nearly a century ago. Next to patients, this $160 million market cap company stand to reap all the rewards…